Karlberg B E, Kågedal B, Tegler L, Tolagen K
Br Med J. 1976 Jan 31;1(6004):251-4. doi: 10.1136/bmj.1.6004.251.
In a crossover study 32 patients with hypertension were randomly allocated to treatment with spironolactone 200 mg/day for two months, propranolol 320 mg/day for two months, and a combination of both drugs at half the dose. Between the treatments placebo was given for two months. Both spironolactone and propranolol lowered the blood pressure significantly in both positions. The initial plasma renin activity (PRA) levels ranged from 0-4 to 5-0 mug angiotensin I l-1 h-1, and there was a close correlation between these levels and the effects of the drugs: with increasing PRA the response to propranolol was better while the opposite was true for spironolactone. Spironolactone reduced the blood pressure more at eight than at four weeks, while no such difference could be shown for propranolol. Spironolactone and propranolol together decreased the blood pressure still further irrespective of the initial PRA. All patients achieved a normal supine blood pressure.
在一项交叉研究中,32例高血压患者被随机分配接受以下治疗:每日200毫克螺内酯治疗两个月,每日320毫克普萘洛尔治疗两个月,以及两种药物半量联合治疗两个月。在不同治疗阶段之间给予两个月的安慰剂。螺内酯和普萘洛尔在两种治疗方案中均显著降低血压。初始血浆肾素活性(PRA)水平范围为0.4至5.0微克血管紧张素I升-1小时-1,这些水平与药物疗效之间存在密切相关性:随着PRA升高,对普萘洛尔的反应更好,而对螺内酯则相反。螺内酯在8周时比4周时降压效果更明显,而普萘洛尔则未显示出这种差异。无论初始PRA如何,螺内酯和普萘洛尔联合使用可进一步降低血压。所有患者仰卧血压均恢复正常。